Botanix Pharmaceuticals Limited (ASX:BOT)

Market Cap	313.81M
Revenue (ttm)	5.79M
Net Income (ttm)	-86.40M
Shares Out	1.96B
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,215,835
Average Volume	7,219,329
Open	0.1600
Previous Close	0.1600
Day's Range	0.1550 - 0.1650
52-Week Range	0.1050 - 0.5350
Beta	1.20
RSI	57.53
Earnings Date	Nov 25, 2025

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 11
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BOT

Financial Performance

In 2025, Botanix Pharmaceuticals's revenue was 5.79 million, an increase of 179.74% compared to the previous year's 2.07 million. Losses were -86.40 million, 522.9% more than in 2024.